Clinical Trial

NeuroFinance Human Stress Trial During Financial and Informational Volatility

Study acronym: NFHST
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
Trial Details
NCT Number NCT07622589
Lead Sponsor Truway Health, Inc.
Conditions Psychological Stress, Anxiety, Emotional Stress, Autonomic Nervous System Dysfunction, Sleep Disturbance, Insomnia, Behavioral Health, Cognitive Fatigue +5 more
Enrollment 2,500 participants
Start Date 2026-07-15
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03